Episurf Medical (EPIS-B)

[Savepig]

Oi shit som den har falt da, visste ikke den var så lav. Er jo emisjoner etter emisjoner som har utmattet aksjonærene.

[Alex]

Og at ttt som aksjonærene ofte glemmer litt. Negativ bunnlinje i det uendelige omtrent hjelper heller ikke. Følger litt med på tråden, men jeg har nok med pho som ligner.negativ bunnlinje der og. Kalkulert vil nok noen si.

[Savepig]

Pho og episurf er jo rimelig like selskap på mange måter, bare at pho er flere år lenger nede i løypa

[holmes]

Ja produktet er bra, men interessen lav og dumpingsemisjon gang på gang hjelper ikke. Aksjonærene får trøste seg med at CEO gikk inn med mange millioner på 6 kroner…

[TekBot]

30/04-2019 11:00:00: (EPIS-B.ST) Change in number of shares and votes in Episurf Medical and formal adjustment of resolution to issue new shares in advance of general meeting

Episurf Medical AB (NASDAQ: EPIS B) has on behalf of shareholders in Episurf Medical AB, conversions of class A-shares to B-shares were carried out during April in accordance with the Articles of Association. Through the conversions, the number of A-shares has decreased by 15,200, and the number of B-shares has increased by the same amount.

The total number of shares amounts to 35,113,686, of which 492,877 are A-shares and 34,620,809 are B-shares. The total number of votes after the conversions amounts to 36,099,440.
…

Vis børsmeldingen

As a consequence of the conversion, the board of directors has resolved on a formal adjustment of the resolution to issue in total no more than 70,227,372 new shares which was adopted by the board of directors on 5 April 2019 and which is proposed to be approved by the general meeting on 7 May 2019. The adjusted resolution entails that the maximum number of A-shares that may be issued is adjusted to 985,754 and the maximum number of B-shares is adjusted to 69,241,618, and that further adjustments may be made in the event that additional conversions are carried out before the record date. The adjusted resolution is available at the company’s website: www.episurf.com.

For more  information, please contact:

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: [email protected] ([email protected])

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, trough the agency of the contact person set out above, at 11:00 CEST on April 30, 2019.

http://www.netfonds.no/quotes/release.php?id=20190430.Cision.20190417:BIT:9762:0

[TekBot]

07/05-2019 10:55:00: (EPIS-B.ST) Summary from extraordinary general meeting of Episurf Medical AB (publ)

Episurf Medical AB (publ) (“Episurf Medical” or the “Company”) held an extraordinary general meeting in Stockholm on 7 May 2019 where it was resolved to approve the resolution adopted by the board of directors on 5 April 2019 on a share issue with preferential rights for the shareholders (the “Rights Issue”) and to amend the Company’s articles of association.

Issue of shares with preferential rights for shareholders
…

Vis børsmeldingen

The board resolution approved by the extraordinary general meeting mainly means that the Company shall carry out an issue of A shares and B shares up to a total subscription amount of approximately SEK 98.3 million before transaction related expenses, with preferential rights for the shareholders of the Company to subscribe for new shares in proportion to their previous shareholding. The resolution on the Rights Issue in summary means the following:

· For each one existing share, two new shares will be issued at issue price of SEK 1.40 per new share. If fully subscribed, a total of 70,227,372 new shares will be issued, and the total proceeds will amount to SEK 98,318,320.80.
· The Company’s share capital shall be increased with no more than SEK 21,086,044,64 by a new issue of no more than 985,754 A shares and no more than 69,241,618 B shares, i.e. no more than a total of 70,227,372 new shares.
· The record date for participation in the Rights Issue is 14 May, 2019.
· The subscription period in the Rights Issue takes place between 15 May 2019 and 29 May 2019.

If not all shares issued in the Rights Issue are subscribed for with subscription rights (primary preferential right), the Board of Directors shall decide on the allotment of new A shares and B shares subscribed for without subscription rights in accordance with the principles set out in the resolution on the Rights Issue.

Amendments to the Company’s articles of association 

In order to enable the Rights Issue, the extraordinary general meeting resolved, in accordance with the proposal of the board of directors, to amend (i) § 4 in the articles of association of the Company regarding the limits of the share capital so that the share capital shall be no less than SEK 10,543,022.32 nor exceed SEK 42,172,089.28, and (ii) § 5 in the articles of association of the Company regarding the number of shares so that the number of shares in the company shall be no less than 35,113,686 and no more than 140,454,744.

Preliminary time plan for the Rights Issue

May 10, 2019                        Last day of trading including the right to receive subscription rights

May 13, 2019                        First day of trading excluding the right to receive subscription rights

May 14, 2019                        Record date for participation in the Rights Issue

May 15 - May 27, 2019         Trading in subscription rights

May 15 - May 29, 2019         Subscription period

June 4, 2019                         Publication of the outcome in the Rights Issue

Financial and legal advisors 

Redeye AB acts as financial advisors and DLA Piper Sweden acts as legal advisor to Episurf Medical in connection with the Rights Issue.

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: [email protected]

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: [email protected] ([email protected])

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

IMPORTANT INFORMATION

The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade with shares or other securities in Episurf Medical. No action has been taken, nor will any actions be taken, to permit an offer to the public in any other jurisdiction than Sweden. An invitation to eligible persons to subscribe for shares in Episurf Medical will only be made through the prospectus which Episurf Medical intends to publish on or about 9 May 2019.

The information in this press release may not be published or distributed, directly or indirectly, within or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the “USA”), Australia, Canada, Hong Kong, Japan, New Zealand, South Africa, Switzerland, the United Kingdom or any jurisdiction where doing so might be unlawful, subject to legal restrictions or require other actions than the ones prescribed under Swedish law. Actions in violation of these instructions may constitute a breach of applicable securities law. This press release does not constitute an offer of invitation to acquire or subscribe for shares in the USA. No subscription rights, paid subscribed shares (BTA) or shares or other securities issued by the Company (the “Securities”) have been, nor will they be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or the securities laws in any other state or jurisdiction in the USA and no Securities may be offered, subscribed, used, pledged, sold, retailed, delivered or transferred, directly or indirectly, in or into the United States other than pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. The Securities have not been and will not be approved or registered by the Securities and Exchange Commission (SEC), any state securities authority or other authority in the USA. No such authority has assessed or made any statements about the offer or the accuracy or reliability of the prospectus. To assert the contrary is a criminal act in the USA.

Within the European Economic Area (“EEA”), no offer of Securities is made in any other jurisdiction than Sweden. In other member states in the EEA which have implemented the Directive 2003/71/EC of the European Parliament and of the Council (“Prospectus Directive”), an offer of Securities may only be made in accordance with an exemption from the Prospectus Directive and any relevant implementation measures (including measures to implement the Directive 2010/73/EU of the European Parliament and of the Council).

This press release may contain certain forward-looking statements which reflect Episurf Medical’s current view of future events and financial and operational developments. Words such as “intends”, “estimates”, “expects”, “may”, “plans”, “deems”, “believes”, “assesses”, “anticipates”, “will”, and other similar expressions which imply indications or predictions regarding future developments or trends, and which are not based on historical facts, constitute forward-looking information. Forward-looking information is by nature affiliated with known and unknown risks and uncertainties since it is dependent on future events and circumstances. Forward-looking information does not constitute any guarantee regarding future results or development and the actual outcome may materially differ from forward-looking statements. The information, assessments and forward-looking statements in this press release are only relevant as of the date of this press release and may change without notice.

http://www.netfonds.no/quotes/release.php?id=20190507.Cision.20190507:BIT:3813:0

[TekBot]

09/05-2019 14:30:00: (EPIS-B.ST) Episurf Medical AB (publ) publishes prospectus

Episurf Medical AB (publ) (“Episurf Medical”) announces that the prospectus for the share issue with preferential rights for the shareholders, which was announced by Episurf Medical on 5 April 2019 and approved by the extraordinary general meeting on 7 May 2019, today has been approved by the Swedish Financial Supervisory Authority. The prospectus is now available on Episurf Medical’s website, www.episurf.com. It will also be available on Redeye’s website, www.redeye.se, and the Swedish Financial Supervisory Authority’s website, www.fi.se.

Financial and legal advisors 
…

Vis børsmeldingen

Redeye AB acts as financial advisor and DLA Piper Sweden acts as legal advisor to Episurf Medical in connection with the rights issue.

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: [email protected]

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: [email protected] ([email protected])

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact person set out above, at 14.30 CEST on 9 May 2019.

IMPORTANT INFORMATION

The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade with shares or other securities in Episurf Medical. No action has been taken, nor will any actions be taken, to permit an offer to the public in any other jurisdiction than Sweden. An invitation to eligible persons to subscribe for shares in Episurf Medical will only be made through the prospectus which Episurf Medical intends to publish on or about 9 May 2019.

The information in this press release may not be published or distributed, directly or indirectly, within or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the “USA”), Australia, Canada, Hong Kong, Japan, New Zealand, South Africa, Switzerland, the United Kingdom or any jurisdiction where doing so might be unlawful, subject to legal restrictions or require other actions than the ones prescribed under Swedish law. Actions in violation of these instructions may constitute a breach of applicable securities law. This press release does not constitute an offer of invitation to acquire or subscribe for shares in the USA. No subscription rights, paid subscribed shares (BTA) or shares or other securities issued by the Company (the “Securities”) have been, nor will they be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or the securities laws in any other state or jurisdiction in the USA and no Securities may be offered, subscribed, used, pledged, sold, retailed, delivered or transferred, directly or indirectly, in or into the United States other than pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. The Securities have not been and will not be approved or registered by the Securities and Exchange Commission (SEC), any state securities authority or other authority in the USA. No such authority has assessed or made any statements about the offer or the accuracy or reliability of the prospectus. To assert the contrary is a criminal act in the USA.

Within the European Economic Area (“EEA”), no offer of Securities is made in any other jurisdiction than Sweden. In other member states in the EEA which have implemented the Directive 2003/71/EC of the European Parliament and of the Council (“Prospectus Directive”), an offer of Securities may only be made in accordance with an exemption from the Prospectus Directive and any relevant implementation measures (including measures to implement the Directive 2010/73/EU of the European Parliament and of the Council).

This press release may contain certain forward-looking statements which reflect Episurf Medical’s current view of future events and financial and operational developments. Words such as “intends”, “estimates”, “expects”, “may”, “plans”, “deems”, “believes”, “assesses”, “anticipates”, “will”, and other similar expressions which imply indications or predictions regarding future developments or trends, and which are not based on historical facts, constitute forward-looking information. Forward-looking information is by nature affiliated with known and unknown risks and uncertainties since it is dependent on future events and circumstances. Forward-looking information does not constitute any guarantee regarding future results or development and the actual outcome may materially differ from forward-looking statements. The information, assessments and forward-looking statements in this press release are only relevant as of the date of this press release and may change without notice.

http://www.netfonds.no/quotes/release.php?id=20190509.Cision.20190509:BIT:6578:0

[holmes]

Preliminary time plan for the Rights Issue

May 7, 2019 EGM

May 10, 2019 Last day of trading including the right to receive subscription rights

May 13, 2019 First day of trading excluding the right to receive subscription rights

May 14, 2019 Record date for participation in the Rights Issue

May 15 – May 27, 2019 Trading in subscription rights

May 15 – May 29, 2019 Subscription period

June 4, 2019 Publication of the outcome in the Rights Issue

[holmes]

Presentasjon her

https://www.redeye.se/live/AW-9-maj

[TekBot]

15/05-2019 08:30:00: (EPIS-B.ST) First day of the subscription period in Episurf Medical’s Rights Issue

Today is the first day of subscription period in Episurf Medical AB’s (publ) (“Episurf Medical” or the “Company”) Rights Issue with preferential right for existing shareholders.

“An increasing number of our customers testify that the treatment gap is closing - thanks to the Episealer©-implant. Our goal is to become the standard treatment and we are taking major and important leaps to achieve this” - comments Pål Ryfors, CEO, Episurf Medical.
…

Vis børsmeldingen

If the Rights Issue is fully subscribed, the Company will receive approximately SEK 98.3m before issue costs. For each class A share and each class B share held on the record date of 14 May 2019, shareholders will receive two (2) subscription rights of class A and class B respectively. One (1) class A subscription right entitles to subscription of one (1) class A share and one (1) class B subscription right entitles to subscription of one (1) class B share. If not all shares issued in the Rights Issue are subscribed for with subscription rights (primary preferential right), the Board of Directors shall decide on the allotment of new shares of class A and B subscribed for without subscription rights in accordance with the following:

1. Firstly, shares not subscribed for with primary preferential right shall be offered to all shareholders for subscription (subsidiary preferential right). If shares thus offered for subscription are insufficient for the subscription that takes place through a subsidiary preferential right, the shares shall be divided among subscribing parties in relation to the previous shareholding. To the extent this cannot take place, the shares shall be divided by the drawing of lots.

2. Secondly, the shares shall be allotted to others that have subscribed for new shares without subscription rights, pro rata to the number of shares that each has applied to subscribe for.

3. Ultimately, the shares shall be allotted to those who guaranteed the Rights Issue pursuant to separate guarantee commitments with the Company, with allocation in relation to the size of their respective commitments.

The Rights Issue has been guaranteed through subscription commitments and guarantee undertakings to approximately SEK 68.8m, approximately 70.0 per cent of the Rights Issue. In addition, declarations of intention to subscribe for up to their pro rata share has been received from existing shareholders Rhenman Partners Asset Management AB and a small cap fund owned by a Swedish pension company, amounting to approximately SEK 7.1m. Subscription commitments, subscription guarantees and declarations of intention to subscribe in amount to, in total, approximately SEK 76.0m.

Record date:                                            14 May 2019

Subscription period:                                15 May - 29 May 2019

Trading in subscription rights:                 15 May - 27 May 2019

Trading in paid-up shares (“BTA”):          25 May - until the Rights Issue has been registered

Publication of the outcome in the Rights Issue 4 June 2019

The Prospectus containing full terms and conditions for the Rights Issue as well as other information about the Company has been made available together with an information pamphlet on Episurf Medical’s, Aqurat Fondkommission’s and Redeye’s respective websites (www.episurf.com, www.aqurat.se and www.redeye.se). Subscription forms for subscription without preferential right will be made available on the above-mentioned websites.

Advisors

Redeye AB is financial advisor and DLA Piper Sweden is legal advisor to Episurf Medical in the Rights Issue.

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: [email protected]

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: [email protected] ([email protected])

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

IMPORTANT INFORMATION

The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade with shares or other securities in Episurf Medical. No action has been taken, nor will any actions be taken, to permit an offer to the public in any other jurisdiction than Sweden. An invitation to eligible persons to subscribe for shares in Episurf Medical is only made through the prospectus which Episurf Medical published on 9 May 2019.

The information in this press release may not be published or distributed, directly or indirectly, within or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the “USA”), Australia, Canada, Hong Kong, Japan, New Zealand, South Africa, Switzerland, the United Kingdom or any jurisdiction where doing so might be unlawful, subject to legal restrictions or require other actions than the ones prescribed under Swedish law. Actions in violation of these instructions may constitute a breach of applicable securities law. This press release does not constitute an offer of invitation to acquire or subscribe for shares in the USA. No subscription rights, paid subscribed shares (BTA) or shares or other securities issued by the Company (the “Securities”) have been, nor will they be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or the securities laws in any other state or jurisdiction in the USA and no Securities may be offered, subscribed, used, pledged, sold, retailed, delivered or transferred, directly or indirectly, in or into the United States other than pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. The Securities have not been and will not be approved or registered by the Securities and Exchange Commission (SEC), any state securities authority or other authority in the USA. No such authority has assessed or made any statements about the offer or the accuracy or reliability of the prospectus. To assert the contrary is a criminal act in the USA.

Within the European Economic Area (“EEA”), no offer of Securities is made in any other jurisdiction than Sweden. In other member states in the EEA which have implemented the Directive 2003/71/EC of the European Parliament and of the Council (“Prospectus Directive”), an offer of Securities may only be made in accordance with an exemption from the Prospectus Directive and any relevant implementation measures (including measures to implement the Directive 2010/73/EU of the European Parliament and of the Council).

This press release may contain certain forward-looking statements which reflect Episurf Medical’s current view of future events and financial and operational developments. Words such as “intends”, “estimates”, “expects”, “may”, “plans”, “deems”, “believes”, “assesses”, “anticipates”, “will”, and other similar expressions which imply indications or predictions regarding future developments or trends, and which are not based on historical facts, constitute forward-looking information. Forward-looking information is by nature affiliated with known and unknown risks and uncertainties since it is dependent on future events and circumstances. Forward-looking information does not constitute any guarantee regarding future results or development and the actual outcome may materially differ from forward-looking statements. The information, assessments and forward-looking statements in this press release are only relevant as of the date of this press release and may change without notice.

http://www.netfonds.no/quotes/release.php?id=20190515.Cision.20190514:BIT:2531:0

[Savepig]

Market cap 187 471 675 SEK i skrivende stund, og så skal de hente inn 98 millioner til, så oppsidepotensialet for de som klarer å komme inn på bunnen er jo enormt. Er en del knær i den vestlige verden som verker for å si det mildt.

Men for aksjen er det litt kappløp med døden følelse. Er brent fryktelig mye aksjonærverdier for å komme så langt. Men sympatisk at Pål himself er inne med så mye penger.

[Alex]

Er brent fryktelig mye aksjonærverdier for å komme så langt.

Akkurat som i PHO men de hadde salg av medisin med hud og hår som gjorde den tunge veien lettere, men kursmessig var PHO en katastrofe lenge.

[Hakon]

Nå kan man fint ta 10-50k aksjer make or break lotto kupong. Det episurf sitter på tror jeg er en gullgruve uten like. Spørsmålet er om episurf selv klarer å stå løpet helt ut eller om de blir slukt

[Savepig]

Ja at denne teknologien kommer til å bli en vinner i markedet om noen år er jeg helt trygg på, resultatene ser ut til å tale for seg selv. 6 år inne for flere pasienter nå.

Og er jo patentert i hue og ræva over hele verden.

[Hakon]

Enig. Jeg ser på alt under 3 kroner som regelrett ran. Så fort jeg får inn penger mot sommeren så skal det shoppes

[Savepig]

Håpet for selskapet må være at dette blir den siste emisjonen på bunn og at de videre kan selge enten ukonvertible obligasjoner eller rettede emisjoner på bedre kurser.

98 millioner SEK inn nå gir de runway i et par år, og da må da snart IP-en i seg selv begynne å ha en egenverdi som kan underbygge en mer investorvennlig finansiering?

[Hakon]

Det later jo til at folk er mye mer interessert i å kaste pengene sine etter bullshitcases som WR kontra noe så solid som episurf. Human logic, makes no sense

[Biotec]

Hva tror dere om emisjonen? De slet vel med å få den fulltegnet sist de hadde emisjon?

[holmes]

Sist fikk de vel inn 91.5%

[Biotec]

Nå har de garantister opp til 70%?

Skal vurdere inngang om de får fylt opp kassen og fortsatt er så lavt priset når skattepengene kommer i juni.